Characteristics of Gynecologic Oncology Patients in King Chulalongkorn Memorial Hospital - Complications and Outcome of Pelvic Exenteration

  • Oranratanaphan, Shina (Department of Obstetrics and Gynecology, Faculty of Medicine, Chulalongkorn Memorial Hospital) ;
  • Termrungruanglert, Wichai (Department of Obstetrics and Gynecology, Faculty of Medicine, Chulalongkorn Memorial Hospital) ;
  • Sirisabya, Nakarin (Department of Obstetrics and Gynecology, Faculty of Medicine, Chulalongkorn Memorial Hospital)
  • Published : 2013.04.30


Background: Pelvic exenteration is a procedure which includes enbloc resection of pelvic organs followed by surgical reconstruction. Aims include both cure and palliation but data for pelvic exenteration in Thailand are very limited. Objective: This study was conducted to evaluate characteristics of patients, operative procedure outcomes and complications. Materials and Methods: This retrospective review covered all of the charts of exenteration patients during January 2002 to December 2011. Baseline characteristic of the patients were collected as well as details of clinical results. Results: A total of 13 cases of pelvic exenteration were included. Most underwent total pelvic exenteration (9 cases) and the remainder posterior and anterior exenteration. Their primary cancers were ovarian, cervical and vulva. Mean operative time was 532 minutes (SD 160.2, range 270-750) and estimated blood loss was 2830 ml (1850, 1000-8000). Mean tumor size was 7.33 cm (3.75, 4-15). Mean hospital stay was 35.2 days (29.8, 13-109). The most common post operative complication was urinary tract infection. Overall disease free survival with a negative surgical margin was significantly better than in positive surgical margin patients (p=0.014). Conclusions: Surgical margin was the most significant prognostic factor for disease free survival, in line with earlier studies.


  1. Baiocchi G, Guimaraes GC, Rosa Oliveira RA, et al (2012). Prognostic factors in pelvic exenteration for gynecological malignancies. Eur J SurgOncol, 38, 948-54.
  2. Berek JS, Howe C, Lagasse LD, et al (2005). Pelvic exenteration for recurrent gynecologic malignancy: survival and morbidity analysis of the 45-year experience at UCLA. Gynecol Oncol, 99, 1539.
  3. Brophy PF, Hoffman JP, Eisenberg BL (1994). The role of palliative pelvic exenteration. Am J Surg, 167, 386-90.
  4. Brunschwig A (1948). Complete excision of pelvic viscera for advanced carcinoma. Cancer, 1, 177-83.<177::AID-CNCR2820010203>3.0.CO;2-A
  5. Crowe PJ, Temple WJ, Lopez MJ, et al (1999). Pelvic exenteration for advanced pelvic malignancy. Semm Surg Oncol, 17, 152-60.<152::AID-SSU3>3.0.CO;2-J
  6. Decker PJ, Olsson C, Willaims LA, et al (1976). Pelvic exenteration as palliation of malignant disease. Am J Surg, 131, 509-15.
  7. Diver EJ, Rauh-Hain JA, Del Carmen MG (2012). Total Pelvic Exenteration for Gynecologic Malignancies. Int J Surg Oncol, 2012, 693535.
  8. Eisenkop SM, Nalick RW, Teng NM (1991). Modified posterior exenteration for ovarian cancer. Obstet Gynecol,78, 879-85.
  9. Eisenkop SM, Spirtos NM (2001). Procedures required to accomplish complete cytoreduction of ovarian cancer. Is there a correlation with biologic aggressiveness and survival? Gynecol Oncol, 82, 643-1.
  10. Guimaraes GC, Baiocchi G, Ferreira FO, et al (2011). Palliative pelvic exenteration for patients with gynecologic malignancies. Arch Gynecol Obstet, 283, 1107-12.
  11. Hockel M, Dornhofer N (2006). Pelvic exenteration for gynaecological tumors: achievements and unanswered questions. Lancet Oncol, 7, 837-47.
  12. Houvenaeghel G, Moutardier V, Karsenty G, et al (2004). Major complications of urinary diversion after pelvic exenteration for gynecologic malignancies; a 23-year mono-institutional experience in 124 patients. Gynecol Oncol, 92, 680-3.
  13. Kraybill WG, Lopez MJ, Bricker EM (1988). Total pelvic exenteration as a therapeutic option in advanced malignant disease of pelvis. Surg Gynecol Obstet, 166, 259-63.
  14. Kuhrt MP, Chokshi RJ, Arrese D, et al (2012). Retrospective review of pelvic malignancies undergoing total pelvic exenteration. World J Surg Oncol, 10, 110.
  15. Landoni F, Maneo A, Colombo A, et al (1997). Randomised study of radical surgery versus radiotherapy for stage Ib-IIa cervical cancer. Lancet, 350, 535-40.
  16. Lawhead RA, Clark DGC, Smith DH, et al (1989). Pelvic exenteration for recurrent or persistent gynaecologic malignancies: a 10-year review of the memorial-sloankettering cancer center experience. Gynecol Oncol, 33, 279-82.
  17. Lichtinger M, Averette H, Penalver M, et al (1986). Major surgical procedures for gynecologic malignancy in elderly women. South Med J, 79, 1506-10.
  18. Lopez MJ, Kraybill NJ, Downey RS, et al (1987). Exenterative surgery for locally advanced rectosigmoid cancers. Is it worth while? Surgery, 102, 644-51.
  19. Lopez MJ, Monato WW (1993). Role of extended resection in the initial treatment of locally advanced colorectal carcinoma. Surgery, 113, 365-72.
  20. Lopez MJ (1993). Pelvic exenteration. In: Cady B, Daly J (eds). Atlas of surgical Oncology. Mosby-Year Book, Chicago, 555.
  21. Magrina JF (1990). Types of pelvic exenteration: a reappraisl. Gyneco Oncol, 37, 363-6.
  22. Matthews CM, Morris M, Burke TW, et al (1992). Pelvic exenteration in elderly patients. Obstet Gynecol, 79, 773-7.
  23. Morley EW, Hopkins MP, Lindenauer SM, et al (1989). Pelvic exenteration, university of Michigan: 100 patients at 5 years. Obstet Gynecol, 74, 934-43.
  24. Orr JW Jr, Shingleton HM, Hatch KD, et al (1983). Gastrointestinal complications associated with pelvic exenteration. Am J Obstet Gynecol, 145, 325-32.
  25. Park JY, Choi HJ, Jeong SY, et al (2007). The role of pelvic exenteration and reconstructive treatment of advanced or recurrent gynecologic malignancies: Analysis of risk factors predicting recurrence and survival. J Surg Oncol, 96, 560-8.
  26. Powlik TM, Skibbes JM, Rodriguez Bigaz MA (2006). Educational review, Pelvic exenteration for advanced pelvic malignancies. Annuals Surgical Oncology, 13, 612-23
  27. Roberts WS, Cavanagh D, Bryson SC, et al (1987). Major morbidity after pelvic exenteration: a seven-year experience. Obstet Gynecol, 69, 617-21.
  28. Sasson AR, Singurdson ER (2000). Management of locally advanced rectal cancer. Dis colon rectum, 43, 1695-701.
  29. Schmidt AM, Imesch P, Fink D, Egger H (2012). Indications and long-term clinical outcomes in 282 patients with pelvic exenteration for advanced or recurrent cervical cancer. Gynecol Oncol, 125, 604-9.
  30. Sharma S, Odunsi K, Discoll D, et al (2005). Pelvic exenteration for gynecological malignancies: twenty year experience at Rosewell Park Cancer Institute. Int J Gynecol Cancer, 15, 475-482.
  31. Soper JT, Berchuck A, Creasman WT, et al (1989). Pelvic exenteration: factors associated with major surgical morbidity. Gynecol Oncol, 35, 93-8.
  32. Talledo OE (1985). Pelvic exenteration-Medical College of Georgia experience. Gynecol Oncol, 22, 181-8.
  33. Tarrazo HM, Ellerkmann RM (1998). Pelvic radical surgery. Surg Oncol Clin North Am, 7, 399-416.
  34. Zoucas E, Frederiksen S, Lydrup ML, et al (2010). Pelvic exenteration for advanced and recurrent malignancy. World J Surg, 34, 2177-84.